智通财经APP获悉，永泰生物-B(06978)午后涨超9%，截至发稿，涨9.65%，报2.5港元，成交额66.03万港元。
消息面上，永泰生物近期公布，集团的产品CAR-T–19注射液(一种抗CD19单链抗体嵌合抗原受体T细胞注射液)获得国家药品监督管理局药品审评中心颁发的突破性疗法认定，用于治疗25岁及以下复发╱难治B细胞急性淋巴细胞白血病患者。该认定乃基于CAR-T–19注射液可靠的临床疗效及安全性数据。其将加快CAR-T–19注射液的临床开发，并加速其早日与患者见面。
据悉，目前全球只有一款CAR-T产品获批用于治疗儿童及青少年复发/难治B细胞急性淋巴细胞白血病（25岁及以下），国内尚无针对治疗儿童及青少年该适应症的CAR-T产品上市。此外，永泰生物具备符合GMP体系的质粒和慢病毒载体生产技术平台和质量检验平台，生产的第三代慢病毒载体基因修饰系统，技术水平和生产工艺处于国内领先水平。自主可控且成本相对较低。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.